1
|
Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, Aslam A, Siddiqui S, Agarwal C, Malyshev Y, Henriquez-Felipe C, Sharma D, Sharma S, Chukwuka N, Rodriguez DC, Alliu S, Le J, Shani J. Corrigendum to: Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM 2023; 116:733. [PMID: 33447849 PMCID: PMC8108631 DOI: 10.1093/qjmed/hcaa266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- G Rojas-Marte
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
- Department of Cardiology, Staten Island University
Hospital-Northwell Health, 475 Seaview Avenue, Staten Island, NY
10305, USA
| | - M Khalid
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - O Mukhtar
- Department of Pulmonology, Interfaith Medical
Center, 1545 Atlantic Avenue, Brooklyn, NY 11213, USA and
| | - A T Hashmi
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - M A Waheed
- Department of Internal Medicine, Maimonides Medical
Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Ehrlich
- Department of Internal Medicine, Maimonides Medical
Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - A Aslam
- Department of Internal Medicine, Maimonides Medical
Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Siddiqui
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - C Agarwal
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - Y Malyshev
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - C Henriquez-Felipe
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - D Sharma
- Department of Internal Medicine, Maimonides Medical
Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Sharma
- Department of Internal Medicine, Maimonides Medical
Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - N Chukwuka
- Department of Internal Medicine, Maimonides Medical
Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - D C Rodriguez
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Alliu
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - J Le
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - J Shani
- From the Department of Cardiology, Maimonides
Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| |
Collapse
|
2
|
Rojas-Marte G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, Aslam A, Siddiqui S, Agarwal C, Malyshev Y, Henriquez-Felipe C, Sharma D, Sharma S, Chukwuka N, Rodriguez DC, Alliu S, Le J, Shani J. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM 2020; 113:546-550. [PMID: 32569363 PMCID: PMC7337835 DOI: 10.1093/qjmed/hcaa206] [Citation(s) in RCA: 97] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 06/10/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND COVID-19 is an ongoing threat to society. Patients who develop the most severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has the potential to improve outcomes in these patients by preventing the development of cytokine release storm. AIMS To evaluate the outcomes of patients with severe COVID-19 disease treated with the interleukin-6 inhibitor tocilizumab. METHODS We conducted a retrospective, case-control, single-center study in patients with severe to critical COVID-19 disease treated with tocilizumab. Disease severity was defined based on the amount of oxygen supplementation required. The primary endpoint was the overall mortality. Secondary endpoints were mortality in non-intubated patients and mortality in intubated patients. RESULTS A total of 193 patients were included in the study. Ninety-six patients received tocilizumab, while 97 served as the control group. The mean age was 60 years. Patients over 65 years represented 43% of the population. More patients in the tocilizumab group reported fever, cough and shortness of breath (83%, 80% and 96% vs. 73%, 69% and 71%, respectively). There was a non-statistically significant lower mortality in the treatment group (52% vs. 62.1%, P = 0.09). When excluding intubated patients, there was statistically significant lower mortality in patients treated with tocilizumab (6% vs. 27%, P = 0.024). Bacteremia was more common in the control group (24% vs. 13%, P = 0.43), while fungemia was similar for both (3% vs. 4%, P = 0.72). CONCLUSION Our study showed a non-statistically significant lower mortality in patients with severe to critical COVID-19 disease who received tocilizumab. When intubated patients were excluded, the use of tocilizumab was associated with lower mortality.
Collapse
Affiliation(s)
- G Rojas-Marte
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
- Department of Cardiology, Staten Island University Hospital-Northwell Health, 475 Seaview Avenue, Staten Island, NY 10305, USA
| | - M Khalid
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - O Mukhtar
- Department of Pulmonology, Interfaith Medical Center, 1545 Atlantic Avenue, Brooklyn, NY 11213, USA
| | - A T Hashmi
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - M A Waheed
- Department of Internal Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Ehrlich
- Department of Internal Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - A Aslam
- Department of Internal Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Siddiqui
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - C Agarwal
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - Y Malyshev
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - C Henriquez-Felipe
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - D Sharma
- Department of Internal Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Sharma
- Department of Internal Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - N Chukwuka
- Department of Internal Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - D C Rodriguez
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - S Alliu
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - J Le
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| | - J Shani
- Department of Cardiology, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA
| |
Collapse
|